Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKACA | P17612 | 8/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.83 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.83 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.82 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10001410 | 0.90 | PRKACA (0.83) | PRKACAADORA3ADORA2AROCK2HSP90B1 | |
| SCHEMBL32660834 | 0.89 | PRKACA (1.00) | PRKACAADORA3ADORA2AROCK2HSP90B1 | |
| SCHEMBL13157206 | 0.87 | PRKACA (0.81) | PRKACAADORA3ADORA2AROCK2HSP90B1 | |
| SCHEMBL10001415 | 0.86 | PRKACA (0.79) | PRKACAADORA3ADORA2AROCK2HSP90B1 | |
| SCHEMBL31409360 | 0.86 | PRKACA (1.00) | PRKACAROCK2 | |
| SCHEMBL25047825 | 0.86 | AHCY (0.84) | ADORA3ADORA2AHSP90B1 | |
| SCHEMBL30941230 | 0.86 | AHCY (0.84) | ADORA3ADORA2AHSP90B1 | |
| SCHEMBL14178249 | 0.83 | ADORA3 (0.82) | PRKACAADORA3ADORA2AROCK2HSP90B1 | |
| SCHEMBL17294015 | 0.82 | PRKACA (0.75) | PRKACAROCK2HSP90B1 | |
| SCHEMBL17294035 | 0.82 | PRKACA (0.75) | PRKACAROCK2HSP90B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4107166-B1 | HETEROARYL COMPOUNDS FOR TREATMENT OF COMPLEMENT FACTOR D MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12558398-B2 | Inflammatory disease treatment with complement inhibitors | UCB HOLDINGS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-12479856-B2 | Pharmaceutical compounds for the treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-12338230-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250197403-A1 | HETEROARYL COMPOUNDS FOR TREATMENT OF COMPLEMENT FACTOR D MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2025-06-19 | — | — | US | disclosed |
| US-12297205-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| EP-3985002-B1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2025-05-07 | — | — | EP | disclosed |
| EP-3589628-B1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2025-05-07 | — | — | EP | disclosed |
| EP-3841086-B1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| US-12239645-B2 | Targeted dosing for the treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| EP-4034237-A1 | METHOD OF TREATMENT OF HEMATOPOIETIC STEM CELL TRANSPLANT ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA) | Volution Immuno Pharmaceuticals SA (CH) | 2022-08-03 | — | — | EP | disclosed |
| US-20220211799-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT ACTIVITY | UCB HOLDINGS, INC. | 2022-07-07 | — | — | US | disclosed |
| US-20220160820-A1 | MODULATORS OF COMPLEMENT ACTIVITY | RA PHARMACEUTICALS, INC. | 2022-05-26 | — | — | US | disclosed |
| US-20220133841-A1 | NEUROLOGICAL DISEASE TREATMENT WITH ZILUCOPLAN | RA PHARMACEUTICALS, INC. | 2022-05-05 | — | — | US | disclosed |
| US-20220119400-A1 | QUINAZOLINE AND INDOLE COMPOUNDS TO TREAT MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2022-04-21 | — | — | US | disclosed |
| EP-3985002-A1 | ARYL, HETEROARY, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| WO-2022066774-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| US-20220079943-A1 | TARGETED DOSING FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2022-03-17 | — | — | US | disclosed |
| US-11244744-B2 | Risk evaluation and management strategy involving patient follow-ups relating to the use or discontinuation of a complement inhibitor | ALEXION PHARMACEUTICALS, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| EP-3941462-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12239645-B2 | Targeted dosing for the treatment of complement mediated disorders | C5, CFH, C9 | PRKACA 1775/4885ADORA3 3029/4885ADORA2A 2404/4885 |
| US-20220160820-A1 | MODULATORS OF COMPLEMENT ACTIVITY | C5, C1QBP, C9 | PRKACA 2631/4885ADORA3 2032/4885ADORA2A 1742/4885 |
| US-12479856-B2 | Pharmaceutical compounds for the treatment of complement mediated disorders | C5, CFH, C1QBP | PRKACA 2726/4885ADORA3 1557/4885ADORA2A 1612/4885 |
| US-20220211799-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT ACTIVITY | C5, C9, C1QBP | PRKACA 3950/4885ADORA3 1769/4885ADORA2A 925/4885 |
| US-20220119400-A1 | QUINAZOLINE AND INDOLE COMPOUNDS TO TREAT MEDICAL DISORDERS | CFB, TFPI, MAOB | PRKACA 1710/4885ADORA3 730/4885ADORA2A 421/4885 |
| US-12338230-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders | CFD, TFPI, CFH | PRKACA 1617/4885ADORA3 2154/4885ADORA2A 2398/4885 |
| US-20250197403-A1 | HETEROARYL COMPOUNDS FOR TREATMENT OF COMPLEMENT FACTOR D MEDIATED DISORDERS | CFD, CFH, TFPI | PRKACA 995/4885ADORA3 3482/4885ADORA2A 3893/4885 |
| US-12558398-B2 | Inflammatory disease treatment with complement inhibitors | C5, C1R, SRPRB | PRKACA 4616/4885ADORA3 2818/4885ADORA2A 2680/4885 |
| US-20220133841-A1 | NEUROLOGICAL DISEASE TREATMENT WITH ZILUCOPLAN | ACHE, C5, BCHE | PRKACA 3416/4885ADORA3 1918/4885ADORA2A 1713/4885 |
| US-20220079943-A1 | TARGETED DOSING FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C5, CFH, C9 | PRKACA 1775/4885ADORA3 3029/4885ADORA2A 2404/4885 |
| US-12297205-B2 | Macrocyclic compounds for treatment of medical disorders | CFD, TFPI, CFH | PRKACA 2165/4885ADORA3 1909/4885ADORA2A 2969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.